A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)

MC #1-JIT-MCLA-128-CL01

NCT #
Condition(s)
Lung Cancer (NSCLC), Pancreatic Cancer
Molecular Target(s)
HER2, HER3
Drug Classification(s)
Molecular Targeted Therapy
Agents(s)
any treatments that use the protein folate receptor alpha or FRĪ± to work
Phase(s)
I/II

Mechanism of Action

Zenocutuzumab, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3

Purpose

n/a

Location

Mary Crowley Cancer Research - Medical City Dallas

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.

7777 Forest Lane,
Building C-707
Dallas, TX 75230

972.566.3000